Retatrutide is an investigational, once-weekly injectable medication developed by Eli Lilly that targets three hormone receptors—GLP-1, GIP, and glucagon—to manage obesity and type 2 diabetes. Phase 2 trials showed significant results, with participants losing up to 24% of their body weight in 48 weeks, with Phase 3 trials concluding in 2026 and potential FDA approval expected in late 2026 or 2027.
Retatrutide is an investigational, once-weekly injectable medication developed by Eli Lilly that targets three hormone receptors—GLP-1, GIP, and glucagon—to manage obesity and type 2 diabetes. Phase 2 trials showed significant results, with participants losing up to 24% of their body weight in 48 weeks, with Phase 3 trials concluding in 2026 and potential FDA approval expected in late 2026 or 2027.
